Ozurdex

NICE backs Bayer's Eylea in diabetic eye condition. TheInstitute also recommends Allergan's Ozurdex in final guidance. ... Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO).

NICE recommends Ozurdex for diabetic eye condition. Draft guidance cites implant as option for patients with diabetic macular oedema. ... Ozurdex is injected into the eye once every six months and works by suppressing inflammation and preventing oedema

Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this